Literature DB >> 23486532

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.

M Roschewski, M Farooqui, G Aue, F Wilhelm, A Wiestner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23486532      PMCID： PMC4172371          DOI： 10.1038/leu.2013.79

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

Authors:  M V Ramana Reddy; Padmavathi Venkatapuram; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Kimberly A Robell; Balaiah Akula; Benjamin S Hoffman; E Premkumar Reddy
Journal:  J Med Chem       Date:  2011-08-17       Impact factor: 7.446

2.  Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.

Authors:  Irina A Oussenko; James F Holland; E Premkumar Reddy; Takao Ohnuma
Journal:  Cancer Res       Date:  2011-06-06       Impact factor: 12.701

3.  Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.

Authors:  Mahesh Seetharam; Alice C Fan; Mai Tran; Liwen Xu; John P Renschler; Dean W Felsher; Kunju Sridhar; Francois Wilhelm; Peter L Greenberg
Journal:  Leuk Res       Date:  2011-09-14       Impact factor: 3.156

4.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Authors:  Kiranmai Gumireddy; M V Ramana Reddy; Stephen C Cosenza; R Boominathan; R Boomi Nathan; Stacey J Baker; Nabisa Papathi; Jiandong Jiang; James Holland; E Premkumar Reddy
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

5.  Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.

Authors:  Wen Wee Ma; Wells A Messersmith; Grace K Dy; Colin D Weekes; Amy Whitworth; Chen Ren; Manoj Maniar; Francois Wilhelm; S Gail Eckhardt; Alex A Adjei; Antonio Jimeno
Journal:  Clin Cancer Res       Date:  2012-02-14       Impact factor: 12.531

6.  Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

Authors:  Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Loretta Pfannes; Kelsey Loeliger; Zachary Tucker; Xin Tian; Minjung Kwak; Francois Wilhelm; Agnes S M Yong; Irina Maric; Manoj Maniar; Phillip Scheinberg; Jerome Groopman; Neal S Young; Elaine M Sloand
Journal:  Leuk Res       Date:  2012-04-21       Impact factor: 3.156

7.  The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Authors:  Péter Lénárt; Mark Petronczki; Martin Steegmaier; Barbara Di Fiore; Jesse J Lipp; Matthias Hoffmann; Wolfgang J Rettig; Norbert Kraut; Jan-Michael Peters
Journal:  Curr Biol       Date:  2007-02-08       Impact factor: 10.834

8.  ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Authors:  Colby M Chapman; Xiameng Sun; Mark Roschewski; Georg Aue; Mohamed Farooqui; Lawrence Stennett; Federica Gibellini; Diane Arthur; Patricia Pérez-Galán; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents.

Authors:  M V Ramana Reddy; Muralidhar R Mallireddigari; Stephen C Cosenza; Venkat R Pallela; Nabisa M Iqbal; Kimberly A Robell; Anthony D Kang; E Premkumar Reddy
Journal:  J Med Chem       Date:  2007-12-19       Impact factor: 7.446
View more
  10 in total

Review 1.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

2.  Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models.

Authors:  Xiaoping Zhang; Hua Lv; Qingyu Zhou; Rana Elkholi; Jerry E Chipuk; M V Ramana Reddy; E Premkumar Reddy; James M Gallo
Journal:  Mol Cancer Ther       Date:  2014-02-25       Impact factor: 6.261

Review 3.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

4.  Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.

Authors:  Lorenzo Agoni; Indranil Basu; Seema Gupta; Alan Alfieri; Angela Gambino; Gary L Goldberg; E Premkumar Reddy; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-11       Impact factor: 7.038

Review 5.  Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Authors:  Jason R Westin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-07

Review 6.  Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.

Authors:  Alice C Fan; Jennifer J O'Rourke; Dave R Praharaj; Dean W Felsher
Journal:  Expert Opin Investig Drugs       Date:  2013-08-12       Impact factor: 6.206

7.  Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer.

Authors:  K Malinowsky; U Nitsche; K-P Janssen; F G Bader; C Späth; E Drecoll; G Keller; H Höfler; J Slotta-Huspenina; K-F Becker
Journal:  Br J Cancer       Date:  2014-03-11       Impact factor: 7.640

8.  Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.

Authors:  Lars Fransecky; Liliana H Mochmann; Claudia D Baldus
Journal:  Mol Cell Ther       Date:  2015-03-20

Review 9.  Oncogene withdrawal engages the immune system to induce sustained cancer regression.

Authors:  Stephanie C Casey; Yulin Li; Alice C Fan; Dean W Felsher
Journal:  J Immunother Cancer       Date:  2014-07-15       Impact factor: 13.751

10.  Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.

Authors:  Anas Younes; Gilles Salles; Giovanni Martinelli; Robert Gregory Bociek; Dolores Caballero Barrigon; Eva González Barca; Mehmet Turgut; John Gerecitano; Oliver Kong; Chaitali Babanrao Pisal; Ranjana Tavorath; Won Seog Kim
Journal:  Haematologica       Date:  2017-09-29       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.